Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 20, 2011 (euro
adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today announced the
appointment of Christine Boisclair as Senior Vice President, Global Regulatory
Affairs, reporting to Dr. Rajesh Malik, Chief Medical Officer.  In this
position, Ms. Boisclair will lead all global regulatory, quality and compliance
activities for Agennix, including regulatory filings for talactoferrin. 

Rajesh Malik, M.D., Chief Medical Officer, said, "I am very pleased to welcome
Christine Boisclair to Agennix.  She has a strong track record of getting drugs
approved in both Europe and the U.S., including a drug for non-small cell lung
cancer.  Her extensive expertise in overseeing novel therapies through the
regulatory review process will be invaluable as we advance talactoferrin through
development and prepare for a potential regulatory filing if the FORTIS-M trial
is positive."

Ms. Boisclair has over twenty years of U.S. and European regulatory affairs
experience, covering both drugs and biologics in a variety of therapeutic areas,
including oncology and anti-infectives. She joins Agennix from OSI
Pharmaceuticals, Inc., where she worked for over ten years in positions of
increasing responsibility, most recently serving as Vice President, Regulatory
Affairs.  At OSI, she built up the regulatory affairs department and served as
the regulatory lead for the successful New Drug Application (NDA) for Tarceva®
(erlotinib) in non-small cell lung cancer (NSCLC), as well as the subsequent
supplemental NDAs for pancreatic cancer and NSCLC maintenance.  Prior to OSI,
she worked at several biotechnology and pharmaceutical companies, including
Genzyme Corporation, GD Searle & Co. and Glaxo Group Research.  She holds a
Bachelor of Science Honors Degree in Biochemistry from York University, York,

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer, and a Phase II/III trial with talactoferrin in severe sepsis
is underway. Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of
talactoferrin for diabetic foot ulcers. Agennix's registered seat is in
Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional information,
please visit the Agennix Web site at

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Even if the results
from our later stage trials with talactoferrin, including the ongoing FORTIS-M
trial in non-small cell lung cancer, are considered positive, there can be no
guarantee that they will be sufficient to gain marketing approval in the United
States or any other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to support
approval.  In such event, there can be no guarantee that the Company will have
or be able to obtain the financial resources to conduct any such additional
studies or that such studies will yield results sufficient for approval. 
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.
Tarceva® is a registered trademark of OSI Pharmaceuticals, Inc.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 		
Phone: +49 (0)89 8565 2693
In the U.S.: Laurie Doyle		
Senior Director, Investor Relations & Corporate Communications		
Phone: +1 609 524 5884
Additional media contact for Europe:	
MC Services AG	
Raimund Gabriel	
Phone: +49 (0) 89 210 228 0
Additional investor contact for Europe:	
Trout International LLC	
Lauren Williams, Vice President	
Phone: +44 207 936 9325

end of announcement                               euro adhoc 

company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: AGENNIX AG

Das könnte Sie auch interessieren: